CytomX Therapeutics (NASDAQ:CTMX) Coverage Initiated at Cantor Fitzgerald

Key Points

• CytomX Therapeutics has been upgraded to a "strong-buy" rating by Cantor Fitzgerald, with projected earnings of ($0.01) EPS for FY2025 and ($0.29) EPS for FY2026.
• The stock currently has a consensus rating of "Buy" among analysts, with an average price target of $5.42 and a recent share price of $2.06.
• Institutional investors and hedge funds currently hold 67.77% of CytomX Therapeutics' stock, indicating strong institutional interest in the company.

Equities research analysts at Cantor Fitzgerald initiated coverage on shares of CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) in a report issued on Monday, MarketBeat.com reports. The brokerage set an "overweight" rating and a $6.00 price target on the biotechnology company's stock. Cantor Fitzgerald's price target would suggest a potential upside of 191.26% from the company's current price. Cantor Fitzgerald also issued estimates for CytomX Therapeutics' FY2025 earnings at ($0.01) EPS and FY2026 earnings at ($0.29) EPS.

A number of other brokerages have also commented on CTMX. Oppenheimer assumed coverage on CytomX Therapeutics in a report on Thursday, July 31st. They set an "outperform" rating and a $7.00 price target for the company. Barclays initiated coverage on CytomX Therapeutics in a report on Wednesday, September 17th. They set an "overweight" rating and a $3.50 price target for the company. Two analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $5.42.

CytomX Therapeutics Stock Performance

CTMX opened at $2.06 on Monday. The business has a 50 day moving average price of $2.15 and a 200 day moving average price of $1.73. CytomX Therapeutics has a twelve month low of $0.40 and a twelve month high of $3.10. The firm has a market cap of $339.71 million, a P/E ratio of 3.68 and a beta of 2.18.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Invesco Ltd. bought a new position in shares of CytomX Therapeutics during the second quarter worth about $32,000. Pursue Wealth Partners LLC bought a new position in shares of CytomX Therapeutics during the second quarter worth about $33,000. Vanguard Personalized Indexing Management LLC grew its holdings in shares of CytomX Therapeutics by 63.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 28,966 shares of the biotechnology company's stock worth $66,000 after buying an additional 11,258 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of CytomX Therapeutics by 188.6% during the second quarter. Tower Research Capital LLC TRC now owns 29,661 shares of the biotechnology company's stock worth $67,000 after buying an additional 19,384 shares in the last quarter. Finally, Lazard Asset Management LLC grew its holdings in shares of CytomX Therapeutics by 5,208.3% during the second quarter. Lazard Asset Management LLC now owns 43,316 shares of the biotechnology company's stock worth $98,000 after buying an additional 42,500 shares in the last quarter. 67.77% of the stock is currently owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.